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ABSTRACT 
This l-month, randomized, double-masked, parallel-group study was 
conducted to compare nimesulide (100 mg twice daily) with diclo- 
fenac (50 mg three times daily) with respect to gastroduodenal tol- 
erability and efficacy in patients with osteoarthritis. Results of gas- 
troduodenal endoscopy in 83 patients (42 receiving nimesulide, 41 
receiving diclofenac) revealed that, after 30 days, 4 patients 
(1 nimesulide, 3 diclofenac) had developed ulcers and 6 patients 
(4 nimesulide, 2 diclofenac) had developed erosions; however, dif- 
ferences between the treatment groups were not statistically sig- 
nificant. Both study drugs were well tolerated. Ten patients (5 in 
each group) withdrew from the study prematurely because of ad- 
verse events. Efficacy was assessed by measuring pain on visual 
analogue scales, using the functional index of Lequesne, and by 
scoring spontaneous pain, pain on passive movement, and functional 
impairment. Nocturnal pain was also checked. All efficacy variables 
showed a significant improvement during the study, and no statis- 
tically signiiicant differences were observed between the treatment 
groups. Key words: nimesulide, diclofenac, gastroduodenal toler- 
ability, osteoarthritis. 
INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin 
(PG) synthesis by blocking cyclooxygenase (COX) pathways. Although ben- 
eficial in reducing pain and inflammation in arthritic joints, decreased PG 
formation has potentially serious consequences in the gastrointestinal mu- 
cosa, where endogenous PCs (mainly prostaglandin E, [PGE,], produced 
by COX-1) are involved in maintaining protective mechanisms.1-3 PGE, 
promotes the production of mucus and bicarbonate and, together with 
prostaglandin I2 (PGI,) helps to maintain mucosal vasodilation; PGE, 
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alone may play a role in reducing acid secretion. Therefore, an NSAID that 
exerts a weaker effect on COX-1 than on COX-2 (inflammatory-PG pro- 
ducing) activity might reduce the risk of lesions in the gastrointestinal 
tract. 
Nimesulide is an NSAID belonging to a new chemical class. It is 
weakly acidic (pKa = 6.5) because of its sulfonanilide functional group. In 
rats, at pharmacologically active doses, nimesulide does not alter the 
amounts of PGE,, PGI,, or thromboxane A2 in the gastric mucosa.4 In 
comparison with other NSAIDs, nimesulide demonstrates little ulcero- 
genie activity in rats.!jp6 
Data on COX-BKOX-1 inhibition show preferential activity of nime- 
sulide on COX-2: the COX-BICOX-1 ratio varies according to the type of 
model from 0.7 to 0.0004.7,8 COX-2 selectivity of nimesulide was confirmed 
recently in a controlled study in humans.g 
Endoscopic studies in humans confirmed the tolerability of nimesulide 
in the gastrointestinal tract. In a double-masked, comparative trial” using 
high dosages of nimesulide (up to 400 mg/d) or placebo administered for 
1 week to dyspeptic patients, no between-group difference in gastric mu- 
cosal damage was observed gastroscopically. A single-masked study” con- 
cluded that nimesulide 200 mg/d was as effective as indomethacin 150 
mg/d in the treatment of articular inflammatory disease but caused less 
gastric mucosal damage. 
The primary aim of the present study was to assess the gastroduo- 
denal tolerability of nimesulide in patients with osteoarthritis (OA). A 
secondary aim was to compare the efficacy of nimesulide with that of 
diclofenac. 
PATIENTS AND METHODS 
This study was designed to be a multicenter, randomized, double-masked 
comparison of parallel groups that included approximately 100 patients 
with OA of the hip or knee. The patients were separated into blocks of 10 
and randomly assigned to receive either nimesulide 100 mg twice daily 
(BID) or diclofenac 50 mg three times daily (TID) according to a computer- 
generated code. The study medications were visually indistinguishable 
and had identical packaging and labeling. Each participating patient re- 
ceived two boxes of medication marked box A, which contained 70 tablets 
(35 for morning and 35 for evening administrations), and one marked box 
B, which contained 35 tablets for administration at midday. Patients in the 
nimesulide group received a visually identical placebo tablet to take at 
midday. Enough medication was supplied for an additional week after the 
study period. If required, patients were permitted to take paracetamol500 
mg/tablet, to a maximum of 6 tablets/d, for additional analgesia. 
GASTRODUODENAL TOLEFtABILITY OF NIMESULIDE 
Patients of either sex, Xi0 years of age, were recruited for the study if 
they had given their written informed consent to participate and had un- 
dergone a washout period following their previous NSAID therapy (48 
hours for nonoxicam-class NSAIDs and 72 hours for oxicam-class 
NSAIDs). Patients also had to fulfill the following entry criteria: endo- 
scopic findings of normal gastroduodenal mucosa or 6 10 petechiae (scored 
0 or 1; Table I>; OA of the hip or knee, with painful exacerbation for more 
than 1 week or requirement for treatment for 1 month with an NSAID, and 
with daily pain (spontaneous or on movement) and functional impairment 
of the affected joint; spontaneous pain intensity scored 24.9 cm on a lo-cm 
Huskisson-type12 visual analogue scale WAS); and lesions rated 1 to 3 
(Table II) seen on radiologic examination for 61 year before study entry. 
Patients were excluded from the study if their OA had been present for 
more than 1 year, if they had severe or incapacitating OA (unable to walk) 
necessitating surgical intervention during the study period, or if they were 
being treated with intra-articular corticoids during the 4 weeks before 
study entry. Patients with severe hepatic, renal, cardiovascular, endocrine, 
or hematologic diseases or bronchial asthma were excluded from the study, 
as were patients with a known history of hypersensitivity reactions to 
NSAIDs (particularly to aspirin or derivatives of propionic acid). Pregnant 
women, nursing mothers, or women who might become pregnant were also 
excluded. 
The use of anticoagulants, hydantoin, oral antidiabetics, antimalari- 
als, other NSAIDs, immunosuppressive agents, central or peripheral an- 
algesics, systemic or intra-articular corticoids, muscle relaxants, neurolep- 
tics, or antidepressants was prohibited during the study. All other 
medications were permitted. Patients were allowed to continue physio- 
therapeutic measures initiated at least 1 month before study entry. 
Participants were scheduled for three visits: 
1. Day -7: Patients underwent endoscopy to determine the status of the 
gastroduodenal mucosa. 
Table I. Scoring criteria for gastroduodenal mucosa as assessed endoscopically. 
Criteria Grade 
Normal mucosa 
l-l 0 Petec hiae 
>lO Petechiae 
l-5 Erosions 
6-10 Erosions 
II-25 Erosions 
>25 Erosions 
Ulcer 
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Table II. Scoring criteria for assessment of osteoarthritis of the knee or hip as assessed 
radiologically. 
Criteria Grade 
Normal 
Slight narrowing of joint space, very slight osteophytosis 
Clear narrowing of joint space, evident osteophytosis, slight osteosclerosis 
Marked narrowing of joint space, evident osteophytosis, periarticular osteosclerosis 
with deformation of bone extremities 
Serious narrowing of joint space, severe osteophytosis, marked periarticular 
osteosclerosis with geodes, severe deformation of bone extremities 
2. 
3. 
Day 0 (baseline): Routine hematologic and serum biochemical analyses 
and urinalysis were performed, and patients began taking their study 
medication. 
Day 30 (final): On completion of the study, patients returned any un- 
used medication (to establish compliance), underwent repeat gastroduo- 
denal endoscopy and laboratory testing, and answered nonleading ques- 
tions about adverse events (Al&), which were graded according to their 
severity, frequency, relationship to the study medication, and outcome. 
Both endoscopic procedures (day -7 and day 30) were performed by the 
same investigator to reduce scoring bias. The investigator also assessed 
the tolerability of the treatment according to a 4-point verbal scale (excel- 
lent, good, fair, poor). 
Compliance was assessed as good if the patient returned ~6 tablets/ 
mo, fair if 7 to 12 tablets, and poor if ~12 tablets (excluding the 21 supple- 
mentary tablets provided for an additional week of treatment). 
EfSicacy Variables 
Spontaneous pain was assessed using a lo-cm VAS. Pain on passive 
motion and functional impairment were assessed using a &point verbal 
scale (absent, mild, moderate, severe, very severe). Functional status was 
assessed using the functional index of Lequesne for OA of the hip and knee 
(25point scale: 0 = healthy subjects, 24 = worst possible case).13 The 
presence of nocturnal pain was checked, and the number of awakenings 
due to pain was recorded. The administration of paracetamol for analgesia 
was analyzed as a secondary efficacy variable. 
Statistical Analysis 
Data entry was done using the dBase IV@ software program (Ashton 
Tate Corp., Maidenhead, United Kingdom), and the statistical analysis 
was performed using SOLO 4.0 (BMDP@ Statistical Software Inc., Los 
Angeles, California) and Testimate@ (Institut fur Datenanalyse und 
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Versuchsplanung [IDVI, Gauting, Germany) on an IBM PS2 personal 
computer. 
The variables assessed for the two treatment groups were compared 
using several statistical tests. Age, body weight, and height were assessed 
using Student’s t test for unpaired data, whereas demographic character- 
istics such as sex and diagnosis were assessed using the chi-square test. 
For the safety variables, the Mann-Whitney U test was used for endoscopic 
scores and judgment; laboratory data were assessed using Student’s t test 
for paired data. For three measures of efficacy-VAS, functional index, and 
pain scores-within-group differences were assessed using Wilcoxon’s 
rank sum test and between-group differences were assessed using the 
Mann-Whitney U test; judgment and compliance data were assessed using 
the Mann-Whitney U test. 
All tests were two-tailed, and a significance level of 0.05 was chosen. 
RESULTS 
Eighty-nine patients (14 men and 75 women) entered the study: 44 were 
randomized to receive nimesulide and 45 to receive diclofenac. However, 
1 patient in the diclofenac group was excluded from both the safety and 
efficacy analyses because of changed dosage, which was considered a major 
protocol violation. Safety analyses were performed on 88 patients, al- 
though final endoscopic findings were available for only 83 patients. Effk 
cacy analyses were performed on data from 77 patients. Six patients with 
endoscopic findings were treated only 10 to 15 days; therefore, they were 
included in the safety analysis but not in the efficacy analysis. The two 
treatment groups were similar with respect to demographic characteristics 
and localization of OA. Thirty-six patients (82%) in the nimesulide group 
and 35 patients (78%) in the diclofenac group had OA of the knee. In 
patients with bilateral involvement of the hip or knee, the more affected 
joint was assessed. 
Sqf.etg Profile 
Clinical Tolerability 
Twenty-two patients (11 in each group) experienced one or more AEs, 
which generally affected the gastrointestinal tract; 5 of the 11 patients in 
each group discontinued treatment prematurely because they developed 
ulcers (1 nimesulide, 3 diclofenac) or erosions (4 nimesulide, 2 diclofenac). 
Table III summarizes the incidence of AEs and their severity. The rela- 
tionship of AEs to the study medication as judged by the investigator is 
shown in Table IV. 
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Table III. Incidence and severity of adverse events (AEs) reported during the study. 
Adverse Events 
Nimesulide Diclofenac 
(n-44) (n = 44)* 
Incidence 
C%;;Agia 
Sensation of fullness/bloating 
Abdominal pain 
Dizziness 
Headaches 
Skin disorders 
g;tosvascular disorders 
Total AEs 
SetivdQ 
Moderate 
Severe 
: 
3 
1 
I, 
3 
1: 
* One patient was withdrawn from the study because of a protocol violation. 
Gastroduodenal Tolerability 
Patients were included in the study only if the results of the baseline 
endoscopic examination (day -7) were normal (Table V). At day 30, most of 
the patients showed normal endoscopic findings, although 4 patients 
(1 nimesulide, 3 diclofenac) had developed ulcers. Erosions were observed 
in 6 patients (4 nimesulide, 2 diclofenac). However, the between-group 
differences in endoscopic findings were not statistically significant. 
Biologic Tolerability 
Statistical analyses were not undertaken because the laboratory tests 
were performed at different facilities, using different normal ranges. He- 
matologic variables were normal at baseline and remained within the nor- 
mal range following treatment in all patients except two (one in each 
group) who had increased erythrocyte sedimentation rates on day 30. Se- 
rum aminotransferases were normal at baseline for all patients. However, 
by day 30, one of the diclofenac-treated patients showed a moderate in- 
crease and one of the nimesulide-treated patients showed a marked in- 
Table IV. Relationship of adverse events to the study medication, as judged by the 
investigators. 
DHIQ 
Nimesulide 
Diclofenac 
Definite 
;; 
Probable 
: 
Doubtful 
3 
1 
Not 
Related 
0 
1 
Total 
21 
19 
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Table V. Scoring of gastroduodenal mucosa as assessed by endoscopy. 
Nimesulide Dicloienac 
Grade* 
Day 30 
(Final) 
Gay 0 
(Baseline) 
0 4” 36 44 36 
: 1 
! 3 1 ; 1 
2 
3aI 44 42 7 44t 41 3 
* 0 = normal mucosa; 1 = l-l 0 petechiae; 2 = >lO petechiae; 3 = l-5 erosions; 4 = 6-10 erosions; 5 = 1 l-25 
erosions; 6 = >25 erosions; 7 = ulcer. 
t One pahent was withdrawn from the study because of a protocol violation. 
crease in these levels; the latter patient showed no other abnormalities 
while the diclofenac-treated patient showed an increase in serum amino- 
transferase, alkaline phosphatase, gamma-glutamyltransferase (rGT), 
and creatinine levels. Three patients in the diclofenac group showed an 
increase in serum alkaline phosphatase compared with baseline levels. 
Three patients in the nimesulide group and one in the diclofenac group 
showed increased levels of yGT at day 0 that remained high at day 30. Two 
other patients in the nimesulide group had elevated baseline ?/GT levels 
that normalized by the end of treatment, whereas two patients in the 
diclofenac group had normal -yGT levels at baseline but elevated levels by 
the end of the study. 
Serum bilirubin levels for all patients remained within the normal 
range during the study period. One nimesulide-treated patient had an 
unexplained increase in serum glucose level at day 30, although she had 
withdrawn from the study at day 10 because of a severe AE. In the diclo- 
fenac group, 1 patient had increased serum cholesterol and creatinine 
levels, 1 patient had an increased serum cholesterol level, and 1 patient 
had a slight increase in serum uric acid level at day 30. 
Urinalysis revealed slight proteinuria at baseline in five nimesulide- 
treated patients and six diclofenac-treated patients. The proteinuria wors- 
ened in one patient after receiving diclofenac therapy. 
Judgment of Tolerability 
At the end of the study, the investigator expressed his or her opinion 
regarding the clinical and biologic safety profile of the study medication. 
No statistically significant differences between the two treatments were 
identified. The assessment of biological tolerability substantially reflected 
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Figure 1. Physicians’ assessment of clinical tolerability among patients with normal baseline 
endoscopic findings. 
the clinical assessment (excellent in 95.1% in the nimesulide group and 
90% in the diclofenac group) (Figure 1). 
Based on patient self-assessment using the VAS, spontaneous pain 
decreased significantly in both groups (nimesulide, P c 0.01; diclofenac, 
P c 0.1) following 4 weeks of treatment (Figure 2). The level of spontaneous 
pain did not differ significantly between the two groups. Similarly, the 
functional index total score decreased significantly in both groups (nime- 
sulide, P < 0.01; diclofenac, P < O.l), but the difference in the treatment 
effect of the two drugs was not statistically significant. All other measure- 
ments of efficacy showed a significant improvement following 4 weeks of 
treatment (nimesulide, P c 0.01; diclofenac, P < O.l>, but no statistically 
significant differences in efficacy were observed between the two groups 
(Table VI). 
At day 30, both the investigator and the patient expressed their judg- 
ment regarding the efficacy of the treatment (Table VII). According to the 
investigators, positive (excellent or good) outcomes were observed in 28 
(71.8%) of the patients treated with nimesulide compared with 28 (73.7%) 
of those treated with diclofenac. Similar opinions were expressed by the 
patients: 28 (71.8%) of the nimesulide-treated patients and 27 (71.1%) of 
the diclofenac-treated patients recorded a positive outcome. No statisti- 
cally significant between-group differences in efficacy were found. Five 
patients (3 nimesulide, 5 diclofenac) needed additional analgesia (paracet- 
amol); no statistical assessment was performed because of the small num- 
ber of patients involved. 
Among the nimesulide-treated patients, 30 (76.9%) were assessed as 
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+ Nimesulide 
-*- Diclofenac 
Day 0 
Baseline) 
Visit 
Day 30 
(Final) 
Figure 2. Assessment (mean) of spontaneous pain as recorded by the patients using the 
visual analogue scale. 
compliant with the medication regimen; one patient (2.6%) was classified 
as poorly compliant. Among the diclofenac-treated patients, 29 (76.3%) 
were classified as compliant, whereas no patient in this group was consid- 
ered poorly compliant. No significant between-group differences with re- 
spect to compliance were found. 
Table VI. Measurements of efficacy as reflected in mean (median) pain scores by treatment 
group at baseline (day 0) and study completion (day 30). 
Nimesulide (n = 39) 
Day 0 Day 30* 
(Baseline) (Final) 
Diclofenac (n = 38) 
Day 0 
(Baseline) 
Lequesne functional indexi3$ 
Spontaneous pains 
Pain on passive movementi’ 
Pa:ne;urmg the night 
36 16 36 15 
No 
No. of awakenings due to pain i.51 
Note: Six patients included in the safety analysis were not included in the efficacy analysis because the 
treatment duration lasted 10 to 15 days. 
*PC 0.01. 
t PC 0.1. 
4 25-point scale: 0 = healthy subjects, 24 = worst possible case. 
P 
Assessed based on a lo-cm visual analogue scale. 
1 1 = absent; 2 = mild; 3 = moderate; 4 = severe; 5 = very severe. 
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Table VII. Final assessment of efficacy as judged by the investigators and the patients. 
Excellent Good Moderate Ineffective P 
investigators 
Nimesulide (n = 39) Diclofenac = 
Patients 
(n 38) 15 10 ;39 9 7 ; 0.7304 
Nimesulide (n = 39) Diclofenac (n = 38) 11 11 0.4422 179 8 7 : 
Note: Six patients included in the safety analysis were not included in the efficacy analysis because the 
treatment duration lasted 10 to 15 days. 
l P value assessed by Mann-Whitney U test. 
DISCUSSION AND CONCLUSIONS 
The present study shows that nimesulide (100 mg BID) for 1 month is 
as efficacious as diclofenac (50 mg TID) in relieving the painful symptoms 
of OA and may have slightly better gastroduodenal tolerability than 
diclofenac. 
Nimesulide has been demonstrated in animals and humans to have 
low ulcerogenic potential. The aim of the present study was to compare 
nimesulide with diclofenac with respect to gastroduodenal tolerability and 
efficacy in the treatment of OA. The l-month study period was sufficient 
for ulcerogenic lesions to develop, although the small number of patients 
made it impossible to demonstrate a statistically significant difference in 
gastroduodenal tolerability between the two drugs. The study results 
could, however, be interpreted as nimesulide having a slightly lower ul- 
cerogenic potential than diclofenac. The same number of patients in each 
treatment group experienced a worsening in their gastroduodenal mucosa, 
but a smaller percentage of nimesulide-treated patients (2.3%) than diclo- 
fenac-treated patients (6.8%) developed ulcers. Furthermore, the incidence 
of gastrointestinal-related AEs was lower with nimesulide (42.8%) than 
with diclofenac (68.4%). It is difficult to determine whether these differ- 
ences are correlated with the COX-2 selectivity of nimesulide, because 
diclofenac is an almost indifferent inhibitor of both COX-1 and COX-2. A 
comparison with a more selective COX-1 inhibitor, also investigating the 
effects on gastric and systemic PGs, might provide a definitive answer. 
Assessment of biologic tolerability revealed a slightly higher but sta- 
tistically insignificant incidence of abnormalities in the diclofenac group 
than the nimesulide group. The efficacy of the two drugs was similar. A 
significant improvement at day 30 compared with baseline was apparent 
for all efficacy variables, but no statistically significant difference was 
observed between the two treatments. Previous double-masked stud- 
ies 14,15 of the efficacy of nimesulide in the treatment of OA have demon- 
strated efficacy comparable to that of etodolac, piroxicam, and ketoprofen. 
GASTRODUODENAL TOLJZUBILI’IY OF NIMESULIDE 
The use of NSAIDs has expanded dramatically in the past decade and 
has been accompanied by a proliferation in the number of therapeutic 
alternatives. However, a significant proportion of patients developed AJCs, 
primarily in the upper gastrointestinal tract, ranging from intolerance to 
life-threatening perforations and bleeding. NSAID-induced gastropathy is 
often asymptomatic, with little correlation between dyspeptic symptoms 
and endoscopic lesions. Studies1G-22 indicate that at least 22% of patients 
taking NSAIDs chronically will develop mucosal erosions, peptic ulcer- 
ations, perforations, or bleeding. However, the duration of NSAID therapy 
is not a dependable marker for the risk of gastropathy, because 25% of 
patients with a bleeding peptic ulcer had received NSAID therapy for less 
than 1 month. 
Because of our current experience with NSAIDs, any new drug that 
has a demonstrably reduced potential for inducing gastropathy and is 
shown to be as efficacious as those currently prescribed will have a ready, 
worldwide market. 
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